Clinipace Worldwide, a global digital clinical research organization
(dCRO), and Swiss-based PFC Pharma Focus (PFC) today jointly announced a
definitive merger agreement under which Clinipace Worldwide has acquired all
outstanding shares of privately-held PFC and its subsidiaries. Based in Zurich, Switzerland
– with offices in Germany, Israel and India – PFC is a pan-European contract
research provider focused on drug and medical device development services and regulatory
consulting.
The combination of PFC and Clinipace Worldwide creates a
truly global dCRO with centralized North American, South American, and European
hubs for strategic drug and medical device product development, clinical
operations, data management, regulatory affairs, and GxP/CMC quality assurance.
The companies share a collective vision of helping emerging and mid-tier life
science firms clients serve patients by substantially accelerating the drug and
device development processes via technology-amplified services. Clinipace is
strongly differentiated in the marketplace through its proprietary technology -based
dCRO value proposition which gives clients more control over timelines and
resources, enhanced project visibility, reduced cost, and improved risk
mitigation.
“With this acquisition, our third in the past 18
months, we have assembled the right global footprint and the right mix of
global therapeutic expertise, strategic product development assets and operational
capabilities to uniquely meet the needs of our clients,” commented Jeff
Williams, CEO and Chairman, Clinipace Worldwide.
“Together with the PFC team we’re better positioned to
serve the needs of our clients by quickly and efficiently scaling to support
their global phase 2-3 trials across a number of therapeutic areas and indications.”
“This is a great win for our client base as they now have access to Clinipace’s
extensive experience and capabilities in conducting trials and providing
regulatory consulting across North and South America;
as well as their proven technology (TEMPO(TM) eClinical platform),” said Kurt
Pfister, CEO, European Operations, Clinipace Worldwide (former CEO, PFC Pharma
Focus, Ltd.)
